Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Disease-specific self-efficacy in spasmodic dysphonia patients.

Hu A, Isetti D, Hillel AD, Waugh P, Comstock B, Meyer TK.

Otolaryngol Head Neck Surg. 2013 Mar;148(3):450-5. doi: 10.1177/0194599812472319. Epub 2013 Jan 8.

PMID:
23300221
2.

Error occurred: cannot get document summary

PMID:
25718677

3.

Factors Associated With Patient-perceived Hoarseness in Spasmodic Dysphonia Patients.

Hu A, Hillel A, Meyer T.

J Voice. 2016 Nov;30(6):769.e23-769.e26. doi: 10.1016/j.jvoice.2015.11.003. Epub 2015 Dec 15.

PMID:
26704415
4.

Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.

Meyer TK, Hu A, Hillel AD.

Laryngoscope. 2013 Nov;123 Suppl 6:S1-14. doi: 10.1002/lary.24292.

PMID:
23818277
5.

A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.

Morzaria S, Damrose EJ.

J Voice. 2012 May;26(3):378-80. doi: 10.1016/j.jvoice.2010.07.011. Epub 2010 Oct 16.

PMID:
20951552
6.

Correlation of the Voice Handicap Index-10 (VHI-10) and Voice-Related Quality of Life (V-RQOL) in patients with dysphonia.

Romak JJ, Orbelo DM, Maragos NE, Ekbom DC.

J Voice. 2014 Mar;28(2):237-40. doi: 10.1016/j.jvoice.2013.07.015. Epub 2013 Dec 8.

PMID:
24321582
7.

Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.

Braden MN, Johns MM 3rd, Klein AM, Delgaudio JM, Gilman M, Hapner ER.

J Voice. 2010 Mar;24(2):242-9. doi: 10.1016/j.jvoice.2008.08.003. Epub 2009 May 28.

PMID:
19481417
8.

[Botulinum toxin efficacy in the treatment of patients with spasmodic dysphonia].

Svetel M, Vasić M, Tomić G, Stanković P, Stojanović M, Dragasević N, Dergenc R, Vukasinović M, Pekmezović T, Petrović I, Kostić V.

Vojnosanit Pregl. 2007 Oct;64(10):671-5. Serbian.

PMID:
18041568
9.

Psychological effects of dysphonia in voice professionals.

Salturk Z, Kumral TL, Aydoğdu I, Arslanoğlu A, Berkiten G, Yildirim G, Uyar Y.

Laryngoscope. 2015 Aug;125(8):1908-10. doi: 10.1002/lary.25319. Epub 2015 Apr 17.

PMID:
25892054
10.

Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin.

Dejonckere PH, Neumann KJ, Moerman MB, Martens JP, Giordano A, Manfredi C.

Eur Arch Otorhinolaryngol. 2012 Apr;269(4):1195-203. doi: 10.1007/s00405-011-1890-6. Epub 2011 Dec 31.

11.

Application of the Mandarin Chinese version of the Voice Handicap Index.

Xu W, Han D, Li H, Hu R, Zhang L.

J Voice. 2010 Nov;24(6):702-7. doi: 10.1016/j.jvoice.2009.05.007. Epub 2010 Jan 18.

PMID:
20083377
12.

Emotional symptoms are secondary to the voice disorder in patients with spasmodic dysphonia.

Liu CY, Yu JM, Wang NM, Chen RS, Chang HC, Li HY, Tsai CH, Yang YY, Lu CS.

Gen Hosp Psychiatry. 1998 Jul;20(4):255-9.

PMID:
9719906
13.

Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.

Rubin AD, Wodchis WP, Spak C, Kileny PR, Hogikyan ND.

Arch Otolaryngol Head Neck Surg. 2004 Apr;130(4):415-20.

PMID:
15096423
14.

Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.

Rosow DE, Parikh P, Vivero RJ, Casiano RR, Lundy DS.

Otolaryngol Head Neck Surg. 2013 Jun;148(6):1003-6. doi: 10.1177/0194599813484685. Epub 2013 Mar 27.

PMID:
23535709
15.

Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.

Novakovic D, Waters HH, D'Elia JB, Blitzer A.

Laryngoscope. 2011 Mar;121(3):606-12. doi: 10.1002/lary.21395. Epub 2011 Feb 4.

PMID:
21298641
16.

Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia.

Benninger MS, Gardner G, Grywalski C.

Arch Otolaryngol Head Neck Surg. 2001 Sep;127(9):1083-5.

PMID:
11556856
17.

[Link between depression and academic self-esteem in gifted children].

Bénony H, Van Der Elst D, Chahraoui K, Bénony C, Marnier JP.

Encephale. 2007 Jan-Feb;33(1):11-20. French.

PMID:
17457290
18.

Voice related quality of life after botulinum toxin injection for spasmodic dysphonia.

Gama AC, Menezes LN, Maia AA, Rezende Neto AL, Oliveira JB.

Rev Laryngol Otol Rhinol (Bord). 2010;131(1):39-44.

PMID:
21077414
19.

Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results.

Paniello RC, Barlow J, Serna JS.

Laryngoscope. 2008 Mar;118(3):564-8. doi: 10.1097/MLG.0b013e31815e8be0.

PMID:
18216744
20.

Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.

Rojas GVE, Ricz H, Tumas V, Rodrigues GR, Toscano P, Aguiar-Ricz L.

J Voice. 2017 May;31(3):391.e7-391.e18. doi: 10.1016/j.jvoice.2016.09.029. Epub 2016 Nov 17.

PMID:
27866691

Supplemental Content

Support Center